Masahiro Yasunaga / Visiting Professor / Division of Advanced Cancer Biology
Department of Integrated Biosciences / / Development of cancer diagnosis and treatment utilizing molecular imaging, antibody and drug delivery system(DDS) technology.

Career Summary
1988: Obtained M.D., Kumamoto University School of Medicine.
1988: Medical intern, 1st Department of Surgery, Kumamoto University School of Medicine.
1989: Shimonoseki Kousei Hospital.
1993: Special Research Student, Graduate School of Medicine, Kyoto University.
1996: Obtained Ph.D., Kumamoto University School of Medicine.
1996: Surgeon, Tsuruta Hospital.
1997: Surgeon, Yamaga City Hospital.
1999: Surgeon, 1st Department of Surgery, Kumamoto University School of Medicine.
2002: Researcher, Stem cell biology, RIKEN CDB.
2006: Section head, Investigative Treatment Division, Research Center for Innovative Oncology, National Cancer Center Hospital East.
2012: Unit leader, Developmental Therapeutics, Research Center for Innovative Oncology, National Cancer Center Hospital East.
2015: Unit leader, Division of Developmental Therapeutics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center.
Educational Activities
Other Universities: Tokyo Medical and Dental University, Graduate School of Medical and Dental Sciences, Life Science and Technology Track.
Research Activities
Elucidating the IL-7 signal pathway and its biological significance in lymphocytes (Refs.1,2).
Screening and identifying cancer-specific cell-surface markers using bioinformatics (Refs. 3,4).
Elucidating the mechanism behind chemoresistance by utilizing molecular imaging technology (Refs. 5,6).
Development of innovative antibody therapeutics against unique targets such as tumor-stromata, transporters and lymphoid antigens (Refs. 7-9).
1)Yasunaga M, Wang F, Kunisada T, Nishikawa S, Nishikawa SI. Cell cycle control of c-kit+IL-7R+ B precursor cells by two distinct signals derived from IL-7 receptor and c-kit in a fully defined medium. J Exp Med.  182, 315-323. 1995
2)Yasunaga M, Yagi T, Hanzawa N, Yasuda M, Yamanashi Y, Yamamoto T, Aizawa S, Miyauchi Y, Nishikawa S. Involvement of Fyn tyrosine kinase in progression of cytokinesis of B lymphocyte progenitor. J Cell Biol. 132, 91-99. 1996.
3)Yasunaga M, Nishikawa S,Nakano Y, Tada S, Okada M, Jakt,LM, Nishikawa S, Era T, Nishikawa SI. Induction and monitoring of definitive and visceral endoderm differentiation of mouse ES cells. Nat Biotech. 23, 1542-50. 2005.
4)Yasunaga M, Matsumura Y. Role of SLC6A6 in promoting the survival and multidrug resistance of colorectal cancer. Sci Rep. 4, 4852. 2014.
5)Yasunaga M, Manabe S, Matsumura Y. Tumor stromal barrier and cancer stromal targeting therapy. Microvascular Reviews and Communications. 6, 2-8. 2013.
6)Yasunaga M,Furuta M, Ogata K, Koga Y, Yamamoto Y, Takigahira M,Matsumura Y. The significance of microscopic mass spectrometry with high resolution in the visualisation of drug distribution. Sci Rep. 3, 3050. 2013.
7)Yasunaga M, Manabe S, Tarin D, Matsumura Y. Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. Bioconjug Chem. 22, 1776-83. 2011.
8)Yasunaga M, Manabe S, Matsumura Y. New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots. Cancer Sci. 102, 1396-402. 2011.
9)Yasunaga M, Manabe S, Tarin D, Matsumura Y. Tailored immunoconjugate therapy depending on a quantity of tumor stroma. Cancer Sci. 104, 231-7. 2013.
Other Activities
Japanese Society for Molecular Imaging (JSMI), Director (2015-2018)
The Japan Society of Drug Delivery System, Councilor (2011-present)
Japanese Cancer Association, Councilor (2014-present)
Japanese Society for Microcirculation
Molecular Robotics Research Group
Chem-Bio Informatics Society
Bioimaging Society
Japan Surgical Society
The Japanese Society of Gastroenterological Surgery
The Japanes Asociation for Thoracic Surgery
Japan Society of Clinical Oncology
American Association for Cancer Research (AACR)
World Molecular Imaging Congress (WMIC)
The Antibody Society (MA, USA)
Future Plan
We plan to tackle difficult problems in oncology such as tumor heterogeniety, chemoresistance and metastasis by utilizing molecular imaging, antibody and DDS technology.
We will invent a new type of fully-armed antibody that attacks refractory tumors.
In the coming era of big data, we will embrace a new-style of research that integrates dry and wet science.

Research Activities and Prospect
Research Activities and Prospect

Messages to Students
Research is based on investigating unknown unknowns rather than known unknowns.
You might continuously fail and be tormented. That is why "the joy of scientific discovery" is so very wonderful.
I want to encourage students to try as many new things as possible without fearing failure. This will enable you to really feel the joy.